XKRX
268600
Market cap168mUSD
Mar 23, Last price
6,680.00KRW
Name
Cellivery Therapeutics Inc
Chart & Performance
P/E
—
P/S
13.17
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
18.86b
Net income
-32.57b
CFO
-8.79b
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Cellivery Therapeutics, Inc. researches and develops therapeutic drugs for life-threatening lethal diseases, such as cancer, inflammation, metabolic, and neurodegenerative diseases. It develops small molecule, antibody, and vaccine drugs based on its Therapeutic molecule Systemic Delivery Technology. The company was founded in 2014 and is based in Seoul, South Korea.
Valuation
Title KRW in thousands, except ratios and share amounts | FY |
|---|---|
| 2023‑12 | |
| Income | |
Revenues | |
Cost of revenue | |
Unusual Expense (Income) | |
NOPBT | |
NOPBT Margin | |
Operating Taxes | |
Tax Rate | |
NOPAT | |
Net income | |
Dividends | |
Dividend yield | |
Proceeds from repurchase of equity | |
BB yield | |
| Debt | |
Debt current | |
Long-term debt | |
Deferred revenue | |
Other long-term liabilities | |
Net debt | |
| Cash flow | |
Cash from operating activities | |
CAPEX | |
Cash from investing activities | |
Cash from financing activities | |
FCF | |
| Balance | |
Cash | |
Long term investments | |
Excess cash | |
Stockholders' equity | |
Invested Capital | |
ROIC | |
ROCE | |
| EV | |
Common stock shares outstanding | |
Price | |
Market cap | |
EV | |
EBITDA | |
EV/EBITDA | |
Interest | |
Interest/NOPBT | |